134 related articles for article (PubMed ID: 35489725)
1. Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer.
Klimaite R; Kazokaite M; Kondrotiene A; Dauksiene D; Verkauskiene R; Zilaitiene B; Dauksa A
Anticancer Res; 2022 May; 42(5):2289-2299. PubMed ID: 35489725
[TBL] [Abstract][Full Text] [Related]
2. Altered TEG Parameters Identify Hypercoagulablilty and are of Diagnosis Value for Papillary Thyroid Carcinoma Patients.
Lu S; Kang R; Wang Y; Zhu M; Zhao L; Xu Q; Song Y; Liu C
Exp Clin Endocrinol Diabetes; 2020 May; 128(5):297-302. PubMed ID: 30235493
[TBL] [Abstract][Full Text] [Related]
3. Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer.
Kondrotienė A; Daukša A; Pamedytytė D; Kazokaitė M; Žvirblienė A; Daukšienė D; Simanavičienė V; Klimaitė R; Golubickaitė I; Stakaitis R; Šarauskas V; Verkauskienė R; Žilaitienė B
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899424
[TBL] [Abstract][Full Text] [Related]
4. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.
Pupilli C; Pinzani P; Salvianti F; Fibbi B; Rossi M; Petrone L; Perigli G; De Feo ML; Vezzosi V; Pazzagli M; Orlando C; Forti G
J Clin Endocrinol Metab; 2013 Aug; 98(8):3359-65. PubMed ID: 23788690
[TBL] [Abstract][Full Text] [Related]
5. Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification.
Salvianti F; Giuliani C; Petrone L; Mancini I; Vezzosi V; Pupilli C; Pinzani P
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28672797
[TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Role of Cell-free DNA Integrity in Thyroid Cancer Particularly for Bethesda IV Cytology.
Higazi AM; El Hini SH; El-Sharkawy EA; Gayyed MF; Aziz NA; Matta RA
Endocr Pract; 2021 Jul; 27(7):673-681. PubMed ID: 33601025
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF
Khatami F; Larijani B; Heshmat R; Nasiri S; Haddadi-Aghdam M; Teimoori-Toolabi L; Tavangar SM
J Cell Physiol; 2020 Oct; 235(10):6954-6968. PubMed ID: 32017063
[TBL] [Abstract][Full Text] [Related]
9. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.
Qiao DH; He XM; Yang H; Zhou Y; Deng X; Cheng L; Zhou XY
Am J Otolaryngol; 2021; 42(2):102920. PubMed ID: 33454555
[TBL] [Abstract][Full Text] [Related]
10. Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter.
Hou X; Jiang L; Chen C; Zhu X; Ge M
Clin Lab; 2015; 61(7):793-9. PubMed ID: 26299079
[TBL] [Abstract][Full Text] [Related]
11. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
12. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
[TBL] [Abstract][Full Text] [Related]
13. Complement C4-A and Plasminogen as Potential Biomarkers for Prediction of Papillary Thyroid Carcinoma.
Wang Y; Zhou S; Wang D; Wei T; Zhu J; Li Z
Front Endocrinol (Lausanne); 2021; 12():737638. PubMed ID: 34803909
[TBL] [Abstract][Full Text] [Related]
14. Higher urinary bisphenol A concentration and excessive iodine intake are associated with nodular goiter and papillary thyroid carcinoma.
Zhou Z; Zhang J; Jiang F; Xie Y; Zhang X; Jiang L
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28684549
[TBL] [Abstract][Full Text] [Related]
15. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Chen X; Jin J; Zheng L; Sheng Y; Sun J
J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of serum E-cadherin in patients with papillary thyroid carcinoma].
Sun L; Wang DM; Zhang WJ; Zhang J; Wu JF
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(2):123-126. PubMed ID: 29871201
[No Abstract] [Full Text] [Related]
17. Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis.
Hou F; Sun XD; Deng ZY
Medicine (Baltimore); 2023 Feb; 102(7):e32928. PubMed ID: 36800605
[TBL] [Abstract][Full Text] [Related]
18. lncRNA GAS8-AS1 genetic alterations in papillary thyroid carcinoma and their clinical significance.
Zhou DL; Liu Q; Xu BH; Li Y; Su X; Ye ZL; Zhang X; Peng JL; Deng L; Tang T; Shao Q; Ma JJ; Yang XH; He CY
Cancer Biomark; 2020; 29(2):255-264. PubMed ID: 32675393
[TBL] [Abstract][Full Text] [Related]
19. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
[TBL] [Abstract][Full Text] [Related]
20. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
